陳 茜, 任曉曦, 鄧鄴云, 劉康瑞, 張建亮
(首都醫(yī)科大學(xué)基礎(chǔ)醫(yī)學(xué)院神經(jīng)生物學(xué)系, 北京 100069)
帕金森病(Parkinson’s disease,PD)作為常見的神經(jīng)退行性疾病,其主要的神經(jīng)病理特征是患者的中腦黑質(zhì)致密部的多巴胺能神經(jīng)元的選擇性變性與缺失[1]。目前,PD的發(fā)病機(jī)制仍不清楚,可能的致病因素有線粒體紊亂[2]、氧化應(yīng)激[3]和蛋白質(zhì)的錯(cuò)誤折疊[4]等。越來越多的證據(jù)表明,在PD患者的尸檢報(bào)告和PD動(dòng)物模型中,大腦黑質(zhì)組織中會(huì)發(fā)生小膠質(zhì)細(xì)胞大量激活,且會(huì)伴隨著促炎細(xì)胞因子水平的增加[5, 6]。進(jìn)一步的研究證據(jù)表明,抑制小膠質(zhì)細(xì)胞激活和炎癥因子的釋放可以挽救多巴胺能神經(jīng)元的進(jìn)行性丟失[7]。然而,如何抑制炎癥從而減緩PD的病程仍然是一個(gè)未解的問題。
γ-氨基丁酸(γ-aminobutyric acid,GABA)通過與離子型受體GABAA和代謝型受體GABAB結(jié)合發(fā)揮作用。目前,通過研究表明,GABAA和GABAB受體在中樞神經(jīng)系統(tǒng)的神經(jīng)元和膠質(zhì)細(xì)胞上都有表達(dá)[8, 9]。給予蠅蕈醇(Muscimol,GABAAR激動(dòng)劑)可以激活小鼠抗原提呈細(xì)胞中的GABAA受體,從而減少細(xì)胞中TNF-α、IL-6的升高[10],提示GABA除了眾所周知的離子型作用外,GABA還能發(fā)揮代謝型作用[11]。原代星型膠質(zhì)細(xì)胞和小膠質(zhì)細(xì)胞系中,給予Muscimol后可降低脂多糖(lipopolysaccharide,LPS)誘導(dǎo)的NF-κB (nuclear factor-κ-gene binding,NF-κB)中p65亞基的升高[8],后者是炎癥反應(yīng)的關(guān)鍵組成部分。此外,體外研究還證明,Muscimol可以通過抑制小膠質(zhì)細(xì)胞炎癥因子的釋放,從而進(jìn)一步保護(hù)了神經(jīng)元的活性[12],但是其中具體的機(jī)制仍不清楚。
總之,研究表明,GABAAR激動(dòng)劑似乎可以通過激活小膠質(zhì)細(xì)胞上的GABAAR從而發(fā)揮抗炎作用。本文即驗(yàn)證GABAAR激動(dòng)劑對炎癥因子的抑制作用,并探究其背后的分子機(jī)制。
DMEM培養(yǎng)基和胎牛血清(FBS,Gibco),脂多糖(LPS,Sigma-Aldrich),γ-氨基丁酸(GABA,Sigma),蠅蕈醇(Muscimol,Sigma-Aldrich),印防己毒素(PTX,Tocris),P65抗體(CST),Mouse TNF-α ELISA Kit(北京百智生物科技公司),Mouse IL-6 ELISA Kit(北京百智生物科技公司),雙熒光素酶報(bào)告檢測試劑盒(翌圣生物科技公司),乳酸脫氫酶細(xì)胞毒性檢測試劑盒(碧云天),MTT(Sigma)。
小鼠小膠質(zhì)細(xì)胞(BV2細(xì)胞)或神經(jīng)母細(xì)胞瘤細(xì)胞(SH-SY5Y細(xì)胞)培養(yǎng)于含有10%胎牛血清的DMEM培養(yǎng)基中,待細(xì)胞在培養(yǎng)箱中密度達(dá)到80% ~ 90%時(shí)進(jìn)行傳代,達(dá)到70% ~ 80%時(shí)用PEI進(jìn)行轉(zhuǎn)染。
BV2細(xì)胞培養(yǎng)于96孔板中,使用濃度為1~100 μmol/L GABA/Muscimol預(yù)處理30 min,加入終濃度為1 μg/mL LPS處理12 h;對于GABAAR的氯通道抑制劑Picrotoxin(PTX)在GABA處理前10 min加入到培養(yǎng)基中。收集細(xì)胞培養(yǎng)基,300 g離心10 min。收集離心后的培養(yǎng)基上清液,使用酶聯(lián)免疫吸附測定(ELISA)試劑盒依照說明書的步驟,檢測培養(yǎng)基中腫瘤壞死因子-α(TNF-α)和白介素-6(IL-6)水平。
將細(xì)胞播種于提前用多聚賴氨酸包被35 mm直徑的培養(yǎng)皿,隨后將其培養(yǎng)在37 ℃、5% CO2飽和濕度的條件下,12 h后對其加藥處理。到達(dá)既定時(shí)間后,棄除培養(yǎng)基,用0.01 mol/L PBS清洗3次。隨后用4%多聚甲醛和4%蔗糖的細(xì)胞固定液固定15 min,再用3%牛血清白蛋白和0.1% Triton X-100細(xì)胞封閉液封閉15 min。用0.01 mol/L PBS清洗細(xì)胞5遍,用相應(yīng)的抗體進(jìn)行孵育染色,隨后使用Leica TCS SP5進(jìn)行成像。
BV2細(xì)胞培養(yǎng)于24孔板中,將100 ng報(bào)告基因質(zhì)粒pNF-κB-Luc和10 ng pRL-TK質(zhì)粒用PEI共轉(zhuǎn)染入BV2細(xì)胞。轉(zhuǎn)染48 h后收取細(xì)胞,使用雙熒光素酶檢測試劑盒依照說明書的步驟,測定細(xì)胞的熒光素酶活性。
將細(xì)胞接種于96孔板中。待細(xì)胞長至孔板的40% ~ 60%時(shí),進(jìn)行細(xì)胞轉(zhuǎn)染操作。轉(zhuǎn)染后4 ~ 6 h進(jìn)行細(xì)胞換液,18 h后棄去孔板中培養(yǎng)基,并向每孔加入10 μL 5 mg/mL的MTT溶液,37 ℃繼續(xù)培養(yǎng)4 h。4 h后棄去液體,向每孔加入100 μL DMSO,室溫避光孵育10 min。用酶標(biāo)儀儀器,選擇490 nm波長進(jìn)行檢測。
將細(xì)胞接種于96孔板中,待細(xì)胞密度于40% ~ 60%時(shí)進(jìn)行細(xì)胞加藥處理。其中,加藥處理到達(dá)既定時(shí)間后,取細(xì)胞上清液置于新96孔板中,用LDH細(xì)胞毒性檢測試劑盒(碧云天)測定細(xì)胞的毒性。
之前有文獻(xiàn)[13]報(bào)道,LPS刺激會(huì)造成小膠質(zhì)細(xì)胞的炎癥因子的釋放。因此,本文使用了小鼠小膠質(zhì)細(xì)胞系BV2細(xì)胞,將BV2細(xì)胞接種到96孔板中,培養(yǎng)16~24 h,加入不同濃度的LPS處理12 h,并收集培養(yǎng)基上清。用ELISA法檢測其炎癥因子的釋放情況。結(jié)果顯示:與無處理對照組相比,TNF-α和IL-6的釋放水平與LPS的處理濃度有劑量依賴關(guān)系,與無處理組相比,濃度為10-3~ 100μg/mL的LPS均促進(jìn)了TNF-α和IL-6的釋放(P<0.01,F(xiàn)ig.1A-B)。
LPS刺激后小膠質(zhì)細(xì)胞會(huì)激活,激活的小膠質(zhì)細(xì)胞會(huì)釋放炎癥因子,不斷增多的炎癥因子會(huì)刺激周圍的神經(jīng)元,進(jìn)而導(dǎo)致神經(jīng)元的死亡。為了進(jìn)一步觀察使用經(jīng)LPS刺激后的BV2培養(yǎng)基與SH-SY5Y神經(jīng)母細(xì)胞瘤細(xì)胞共培養(yǎng),進(jìn)一步查看SH-SY5Y細(xì)胞的存活情況。LDH檢測的結(jié)果表明:SY5Y細(xì)胞的損傷情況與LPS使用的濃度有劑量依賴關(guān)系,濃度為10-2~ 100μg/mL的LPS刺激SYSY細(xì)胞后均減少了細(xì)胞的活性(P<0.001)。MTT檢測結(jié)果表明:濃度為10-2~ 100μg/mL的LPS刺激SYSY細(xì)胞后,均使細(xì)胞的數(shù)量減少(P<0.001,F(xiàn)ig.1C-D)。
為了排除這種損傷增加是BV2細(xì)胞死亡導(dǎo)致的,本文用LDH和MTT法檢測了同樣劑量、時(shí)間范圍的LPS對BV2細(xì)胞數(shù)量和活力的影響。結(jié)果顯示,本文中所使用的LPS的劑量、時(shí)間范圍,對BV2細(xì)胞未造成毒性(P>0.05,F(xiàn)ig.1E-H)。
為了進(jìn)一步排除SH-SY5Y細(xì)胞的損傷不是因?yàn)長PS對其造成的直接傷害,使用LDH和MTT法進(jìn)一步檢測。結(jié)果顯示:同上述相同劑量LPS刺激后,SH-SY5Y細(xì)胞的數(shù)量和活力無明顯損傷(P>0.05,F(xiàn)ig.1I-J)。
Fig.1 LPS treatment could promote the release of TNF-α and IL-6 in BV2 cells and cause damage to SH-SY5Y cells (A-B) BV2 cells were treated with 10-3-100 μg/mL LPS for 12 hours. The release of TNF-α and IL-6 was detected by ELSIA. Values are presented as mean ± SD. One-way ANOVA followed by Tukey’s post hoc test. **, P<0.01; ***, P<0.001; ****, P<0.0001 compared with control (n= 3 independent experiments for each group). (C-D)SH-SY5Y cells were treated with conditioned medium from BV2 cells (BV2 CM) stimulated by LPS 10-3-100 μg/mL, and cytotoxicity and cell viability was detected with the LDH and MTT assays. Values are presented as mean ± SD. One-way ANOVA followed by Tukey’s post hoc test. ***, P<0.001; ****, P<0.0001 n.s., not significant, compared with control (n= 6 independent experiments for each group). (E-H) BV2 cells were treated with 10-3-100 μg/mL LPS for 12 hours. Cytotoxicity and cell viability was detected with the LDH and MTT assays. n.s., not significant. Values are presented as mean ± SD. One-way ANOVA followed by Tukey’s post hoc test. n.s., not significant, compared with control (n= 12 independent experiments for each group). (I-J) SH-SY5Y cells were treated with 10-3-100 μg/mL LPS for 12 hours. Cytotoxicity and cell viability were evaluated with the LDH and MTT assays. Values are presented as mean ± SD. One-way ANOVA followed by Tukey’s post hoc test. n.s., not significant, compared with control (n= 9 independent experiments for each group)
上述結(jié)果表明,經(jīng)LPS刺激BV2細(xì)胞后所產(chǎn)生的炎癥因子可以損傷SH-SY5Y細(xì)胞。
先前有文獻(xiàn)報(bào)道,GABA可以抑制LPS誘導(dǎo)的小膠質(zhì)細(xì)胞的激活,從而進(jìn)一步抑制炎癥因子的釋放。為了確證GABA是否可以降低BV2培養(yǎng)基中炎癥因子的水平,用不同濃度的GABA(1、10、50、100 μmol/L)預(yù)處理細(xì)胞30 min,進(jìn)一步使用LPS誘導(dǎo)炎癥因子的釋放。ELISA結(jié)果顯示:與溶劑對照組相比,GABA可以劑量依賴方式降低炎癥因子的表達(dá)。其中,100 μmol/L的GABA顯著降低TNF-α和IL-6的釋放(P<0.001,F(xiàn)ig. 2A-B)。
GABA預(yù)處理是否能保護(hù)神經(jīng)細(xì)胞免受小膠質(zhì)細(xì)胞激活誘導(dǎo)的死亡呢,為此本文進(jìn)一步用GABA預(yù)處理后的BV2培養(yǎng)基繼續(xù)培養(yǎng)SH-SY5Y細(xì)胞12 h。用MTT和LDH法對SH-SY5Y細(xì)胞進(jìn)行細(xì)胞數(shù)量和活性的檢測。結(jié)果顯示,與對照組相比,僅加入1 μg/mL的LPS處理的BV2培養(yǎng)基使SH-SY5Y細(xì)胞損傷顯著(P<0.001);與LPS組相比,GABA預(yù)處理能降低BV2對SH-SY5Y細(xì)胞的損傷,且隨著GABA濃度的增強(qiáng),SH-SY5Y細(xì)胞數(shù)量逐漸增加,細(xì)胞活力逐漸增強(qiáng)(P<0.05,F(xiàn)ig. 2C-D)。
Fig.2 The pretreatment of GABA could reduce the release of TNF-α and IL-6 caused by LPS in BV2 cells, thus protecting the activity of SH-SY5Y cells (A-B). BV2 cells were pretreated with 0, 1, 5, 10, 50,100 μmol/L GABA for 30 minutes and then 1 μg/mL LPS was added. The release of TNF-α and IL-6 was detected by ELSIA. Values are presented as mean ± SD. One-way ANOVA followed by Tukey’s post hoc test. *, P<0.05; **, P<0.01; ***, P<0.001, n.s, not significant, compared with the group treated with LPS (n= 3 independent experiments for each group) (C-D). SH-SY5Y cells were treated with conditioned medium from BV2 cells (BV2 CM) co-treated with 0, 1, 5, 10, 50,100 μmol/L GABA and LPS, cytotoxicity and cell viability was evaluated with the LDH and MTT assays. Values are presented as mean ± SD. One-way ANOVA followed by Tukey’s post hoc test. ####,P<0.0001;compared with the control group, ***, P<0.001; ****, P<0.0001; n.s, not significant, compared with the group treated with LPS (n= 9 independent experiments for each group)
這些數(shù)據(jù)表明,GABA能夠降低LPS誘導(dǎo)的TNF-α和IL-6的釋放,同時(shí)也可以進(jìn)一步減緩對SH-SY5Y細(xì)胞的損傷。
之前有文獻(xiàn)表明,在外周系統(tǒng)中,GABA可以通過激活GABAAR發(fā)揮抑制炎癥的作用。那么,在中樞神經(jīng)系統(tǒng)中,GABA是否能通過激活GABAAR從而發(fā)揮抗炎作用呢?在BV2細(xì)胞中,進(jìn)一步使用GABA與GABAAR的拮抗劑PTX共處理。結(jié)果顯示,PTX可以拮抗GABA介導(dǎo)的抑制炎癥的作用(P<0.05,F(xiàn)ig.3A-B)。為了進(jìn)一步確定GABA是通過GABAAR而發(fā)揮作用的,使用了GABAAR的特異性激動(dòng)劑Muscimol預(yù)處理BV2細(xì)胞。結(jié)果顯示,Muscimol能以劑量依賴的方式降低炎癥因子的釋放。其中,與LPS處理組相比,濃度為10 μg/mL的muscimol顯著減少了TNF-α和IL-6的釋放(P<0.001,P<0.01,F(xiàn)ig. 3C-D)。以上結(jié)果說明,GABA通過激活GABAAR發(fā)揮抑制炎癥的作用。
Fig.3 GABA inhibits inflammation through GABAAR (A-B) BV2 cells were pretreated with 100 μmol/L GABA or GABA+PTX for 30 minutes and then treated with 1 μg/mL LPS for 12 hours. The release of TNF-α and IL-6 was detected by ELISA. Values are presented as mean ± SD. One-way ANOVA followed by Tukey’s post hoc test. **, P<0.01, compared with the group treated with LPS, #, P<0.05, ##, P<0.01, compared with the group treated with LPS+GABA (n= 3 independent experiments for each group). (C-D) BV2 cells were pretreated with 0, 1, 10, 50, 100 μmol/L Muscimol or 10 μmol/L Muscimol and 100 μmol/L PTX for 30 minutes and then added 1 μg/mL LPS for 12 hours. The release of TNF-α and IL-6 was detected by ELSIA. ANOVA followed by Tukey’s post hoc test. **, P<0.01; ***, P<0.001, n.s., not significant, compared with control (n= 3 independent experiments for each group)
為了解析GABA及GABAAR的激動(dòng)劑抑制炎癥因子釋放的分子機(jī)制。有文獻(xiàn)[14]表明,NF-κB只有進(jìn)入細(xì)胞核后才能行駛轉(zhuǎn)錄功能而生成炎癥因子。那么,GABAAR的激動(dòng)劑是否通過抑制NF-κB的入核,從而抑制炎癥因子的釋放呢?為了驗(yàn)證這一假設(shè),本文通過免疫熒光檢驗(yàn)了Muscimol預(yù)處理后p65亞基的核定位。結(jié)果顯示,LPS刺激1 h后,p65核內(nèi)分布升高,而Muscimol預(yù)處理可顯著抑制LPS導(dǎo)致的P65核移位(P<0.0001)。繼而使用了GABAAR的抑制劑PTX預(yù)處理細(xì)胞。結(jié)果顯示,PTX反轉(zhuǎn)了P65核移位現(xiàn)象(P= 0.1122,F(xiàn)ig. 4A)。上述結(jié)果確證了Muscimol可以抑制LPS介導(dǎo)的p65核移位。
Fig.4 GABAAR agonists could inhibit the nuclear translocation of NF-κB (A) The subcellular localization of p65 was evaluated using an anti-p65 antibody. Bar= 75 mm; Bar (magnification)= 25 mm. Comparisons between the control and other group were made based on the statistical analysis of the cells with nuclear localization of p65 counted in three random fields, ####, P<0.0001, compared with control, ****, P<0.0001, n.s., not significant, compared with the group treated with LPS (n= 6). (B) The relative luciferase intensity was determined 6 hours after LPS stimulation, with or without pre-treatment of muscimol. ##, P<0.01, compared with control, **, P<0.01, n.s., not significant, compared with the group treated with LPS (n= 3). ANOVA followed by Tukey’s post hoc test
基于以上數(shù)據(jù),我們提出問題Muscimol的預(yù)處理是否就抑制了p65的轉(zhuǎn)錄活性呢?為了回答這一問題,本文使用了pNF-κB-luc報(bào)告基因質(zhì)粒,pNF-κB-Luc是以pGL6質(zhì)粒為模板,可以用于檢測NF-κB的轉(zhuǎn)錄活性。同時(shí)使用CMV-Renilla質(zhì)粒作為對照組,將pNF-κB-luc和CMV-Renilla以1∶10的比例共轉(zhuǎn)染入BV2細(xì)胞,通過熒光素酶檢測驗(yàn)證NF-κB的轉(zhuǎn)錄活性。結(jié)果顯示,Muscimol預(yù)處理可以顯著降低LPS刺激誘導(dǎo)的熒光素信號(P<0.01);進(jìn)一步使用PTX預(yù)處理細(xì)胞,結(jié)果顯示,PTX抑制了熒光素信號的增高(P= 0.0552,F(xiàn)ig. 4B)。以上結(jié)果共同說明,GABAAR的激動(dòng)劑可以抑制NF-κB的入核,進(jìn)而降低其轉(zhuǎn)錄活性,從而抑制炎癥因子的生成,最終發(fā)揮抑制炎癥的作用。
帕金森病(PD)作為第2常見的神經(jīng)退行性疾病,嚴(yán)重影響人們的身心健康。臨床上,PD患者有嚴(yán)重的運(yùn)動(dòng)障礙和中腦SN區(qū)大量多巴胺能神經(jīng)元丟失的特性[15]。目前,PD病因尚不清楚。越來越多的證據(jù)表明,神經(jīng)炎癥在帕金森病的發(fā)生發(fā)展中發(fā)揮重要作用。當(dāng)神經(jīng)炎癥發(fā)生時(shí),以小膠質(zhì)細(xì)胞為主的免疫細(xì)胞過度激活,釋放促炎因子,導(dǎo)致周圍神經(jīng)元退化[16-18]。LPS是革蘭氏陰性菌細(xì)胞壁的組成部分,可引起炎癥反應(yīng)[19]。有研究表明,在大鼠SN中注射LPS可誘發(fā)PD癥狀[20, 21]。小膠質(zhì)細(xì)胞是中樞神經(jīng)系統(tǒng)中的免疫細(xì)胞,是神經(jīng)炎癥反應(yīng)的主要參與者。有研究報(bào)道,PD患者和PD模型動(dòng)物的SN中存在大量異常激活的小膠質(zhì)細(xì)胞[22, 23]。因此,抑制小膠質(zhì)細(xì)胞的過度激活被認(rèn)為是防治PD的潛在策略。
GABA能信號與免疫調(diào)節(jié)過程密切相關(guān)。因此,GABA可能是調(diào)節(jié)神經(jīng)炎癥,進(jìn)而緩解PD進(jìn)程的潛在治療靶點(diǎn)。之前的研究表明,在人類的小膠質(zhì)細(xì)胞中,GABAAR激動(dòng)劑可以顯著減少小膠質(zhì)細(xì)胞TNF-α和IL-6的釋放水平[8]。Liu等[12]研究結(jié)果表明,在小鼠的PD模型中,GABAAR的激動(dòng)劑改善了小膠質(zhì)細(xì)胞的過度活化。在我們的結(jié)果中也同樣觀察到,在BV2細(xì)胞系中,GABA通過激活GABAAR發(fā)揮抑制炎癥的作用,也可以進(jìn)一步保護(hù)神經(jīng)細(xì)胞免受損傷。
機(jī)制方面:NF-κB是一種經(jīng)典的炎癥途徑,參與細(xì)胞炎癥和許多神經(jīng)系統(tǒng)疾病。有研究報(bào)道,NF-κB信號通路的激活是由細(xì)胞外刺激引起的。這些刺激被細(xì)胞膜上的受體識別,并傳遞到細(xì)胞中,通過信號級聯(lián),激活I(lǐng)κB。當(dāng)IκB被激活會(huì)進(jìn)一步發(fā)生磷酸化進(jìn)而降解,此時(shí)沒有IκB的抑制作用,NF-κB復(fù)合物就會(huì)暴露其入核信號從而轉(zhuǎn)錄相關(guān)的炎癥因子[14]。實(shí)驗(yàn)中,通過細(xì)胞免疫熒光和雙熒光素酶檢測也驗(yàn)證了,Muscimol通過激活GABAAR,明顯抑制了LPS介導(dǎo)的P65核移位及進(jìn)一步的轉(zhuǎn)錄,從而降低了炎癥因子的產(chǎn)生。
盡管本研究中提出GABA-GABAAR-NF-κB信號通路發(fā)揮抗炎效應(yīng)的可能機(jī)制,但是GABAAR激活后是如何進(jìn)一步激活NF-κB信號通路的呢,以及GABAAR是離子型受體,具體是如何發(fā)揮代謝作用呢,以上這些問題仍需進(jìn)一步研究??傊?,本文確證了GABA可以抑制炎癥因子的生成,從而起到神經(jīng)保護(hù)作用,并初步探索了該作用背后的分子機(jī)制。該研究可以為研發(fā)GABA-GABAAR-NF-κB通路的靶向新藥提供重要的理論依據(jù)。針對GABAAR的治療也有望成為PD防治的新策略。
中國生物化學(xué)與分子生物學(xué)報(bào)2022年5期